Bromfenac Ophthalmic Solution 0.07 %: A Review of Its Use After Cataract Surgery

Abstract

The nonsteroidal anti-inflammatory drug bromfenac has recently been reformulated with a lower pH to facilitate a reduction in the concentration of bromfenac (to 0.07%) while ensuring an ocular bioavailability similar to that of the 0.09% formulation. Bromfenac ophthalmic solution 0.07% (hereafter referred to as bromfenac 0.07%) [Prolensa(®)] is a once-daily topical ophthalmic solution available in the USA and Canada for the treatment of postoperative inflammation and the reduction of ocular pain in patients who have undergone cataract surgery. In an integrated analysis of two multicentre, phase III studies, bromfenac 0.07% was significantly more effective than placebo in reducing ocular inflammation and pain. In these studies, bromfenac 0.07% was well tolerated, with significantly lower incidences of adverse events, and adverse events affecting the study eye than with placebo. The most common adverse events in the study eye (eye pain, anterior chamber inflammation, foreign body sensation, photophobia, conjunctival hyperaemia and corneal oedema) occurred in numerically fewer bromfenac 0.07% than placebo recipients. Thus, current evidence suggests once-daily bromfenac 0.07% extends the treatment options currently available for the management of postoperative inflammation and pain following cataract surgery.

A randomized double-masked study to compare the ocular safety, tolerability, and efficacy of bromfenac 0.075% compared with vehicle in cataract surgery subjects

“…Our results add to the recent literature about the analgesic effects of bromfenac postcataract surgery 14–17. In particular, our study used bromfenac 0.075% encased in DuraSite, and our efficacy results were similar to others published on bromfenac 0.07% without DuraSite 16,17.…”

Bromfenac 0.09% ophthalmic solution for postoperative pain and ocular discomfort after cataract surgery with phacoemulsification

“…Противовъзпалителното действие на локалните НСПВС (в частност bromfenac 0.09%) след очна хирургия са добре известни, както и аналгетичният им ефект през постоперативния период (27,(29)(30)(31)(32)(33). Повечето изследвания са насочени към демонстрирането на потискането на възпалителния отговор в предна камера (ПК), а ефективността при облекчаването на болката е само допълнение (30,31,34,35 (30,31,34,35). The aim of the current study was to investigate if bromfenac 0.09% influenced the subjective assessment of quality of vision, light sensitivity, ocular discomfort and pain after uneventful phacoemulsification.…”

Topical bromfenac for prevention and treatment of cystoid macular edema following cataract surgery: a review

“…Six prospective studies and one retrospective analysis compared bromfenac with topical corticosteroids for the prevention of CME following cataract surgery in patients without diabetes or in mixed populations (ie, with or without diabetes) 55–58,60–71. In a prospective, investigator-masked, randomized study, Duong et al60 compared bromfenac 0.09% with prednisolone acetate 1% in patients undergoing phacoemulsification.…”

“…Two publications were identified in which CME outcomes were reported as safety findings in placebo-controlled studies of the efficacy of bromfenac in the treatment of post-cataract surgery inflammation and pain 55,56,71. In an integrated analysis of data from two phase 3, placebo-controlled trials, the incidence of CME was 0.5% among patients treated with bromfenac 0.07% and 1.5% among placebo-treated patients 56,71…”

“…In an integrated analysis of data from two phase 3, placebo-controlled trials, the incidence of CME was 0.5% among patients treated with bromfenac 0.07% and 1.5% among placebo-treated patients 56,71…”